Market Research Logo

Global Artificial Intelligence (AI) Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018

Global Artificial Intelligence (AI) Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018

The Global Artificial Intelligence (AI) LPartnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018 report provides an understanding and access to the Artificial Intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Artificial Intelligence partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Artificial Intelligence partnering contract documents
Top Artificial Intelligence deals by value

The Global Artificial Intelligence Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides an understanding and access to the Artificial Intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Artificial Intelligence partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Artificial Intelligence technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Artificial Intelligence agreements announced in the healthcare sectors, covering:

Artificial Intelligence
AI
Machine learning

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Artificial Intelligence deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Artificial Intelligence dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Artificial Intelligence dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Artificial Intelligence deals since 2010. Deals are listed by headline value, signed by big pharma, most active Artificial Intelligence dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Artificial Intelligence dealmaking with a brief summary followed by a comprehensive listing of Artificial Intelligence deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Artificial Intelligence partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Artificial Intelligence partnering deals signed and announced since Jan 2010. The chapter is organized by specific Artificial Intelligence technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Artificial Intelligence partnering company A-Z, deal type definitions and Artificial Intelligence partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Artificial Intelligence partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Artificial Intelligence technologies and products.

Report scope

Global Artificial Intelligence Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018 is intended to provide the reader with an in-depth understanding and access to Artificial Intelligence trends and structure of deals entered into by leading companies worldwide.

Global Artificial Intelligence Partnering Terms and Agreements 2010 to 2018 includes:

Trends in Artificial Intelligence dealmaking in the biopharma industry since 2010
Analysis of Artificial Intelligence deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Artificial Intelligence deals
Access to over 200 Artificial Intelligence deal records and contract documents where available
The leading antibody deals by value since 2010
Most active Artificial Intelligence dealmakers since 2010
The leading Artificial Intelligence partnering resources

In Global Artificial Intelligence Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


  • Executive Summary
  • Introduction
  • Trends in Artificial Intelligence dealmaking
    • Introduction
    • Artificial Intelligence partnering over the years
    • Most active Artificial Intelligence dealmakers
    • Artificial Intelligence partnering by deal type
    • Artificial Intelligence partnering by therapy area
    • Deal terms for Artificial Intelligence partnering
      • Artificial Intelligence partnering headline values
        • Table Artificial Intelligence deals with a headline value
      • Artificial Intelligence deal upfront payments
      • Artificial Intelligence deal milestone payments
        • Table Artificial Intelligence deals with a milestone value
      • Artificial Intelligence royalty rates
  • Leading Artificial Intelligence deals
    • Introduction
    • Top Artificial Intelligence deals by value
      • Table Top Artificial Intelligence deals by value since 2010
  • Most active Artificial Intelligence dealmakers
    • Introduction
    • Most active Artificial Intelligence dealmakers
    • Most active Artificial Intelligence partnering company profiles
      • GNS Healthcare
      • Tempus
      • IBM
      • IBM Watson Health
      • Microsoft
      • Pfizer
      • Royal Philips Electronics
      • Berg
      • Cohen Veterans Bioscience
      • Leidos Holdings
      • Alliance For Clinical Trials In Oncology
      • Becton Dickinson
      • Benson Hill Biosystems
      • Berg Pharma
      • Brigham and Women's Hospital
      • Cytobank
      • Department of Defense
      • E-Therapeutics
      • Food and Drug Administration (FDA)
      • Georgia Institute of Technology
      • GE Healthcare
      • Henry M. Jackson Foundation
      • Innovate UK
      • Insilico
      • Johnson & Johnson Innovation
  • Artificial Intelligence contracts dealmaking directory
    • Introduction
    • Artificial Intelligence contracts dealmaking directory
  • Artificial Intelligence dealmaking by technology type
    • AI/Artificial intelligence
  • Partnering resource center
    • Online partnering
    • Partnering events
  • Appendices
    • Artificial Intelligence deals by company A-Z
      • A*STAR Bioinformatics Institute
      • A2A Pharmaceuticals
      • Abramson Cancer Center
      • AcuraStem
      • Adaptive Biotechnologies
      • Adapt Analytics
      • Adents
      • Ai-Medic Devices
      • Alberta Innovates Bio Solutions
      • Alberta Innovates Technology Futures
      • Align Technology
      • AliveCor
      • Alliance For Clinical Trials In Oncology
      • ALS Association
      • Althea Technologies
      • Al Bio Tech
      • American Sleep Apnea Association
      • Amgen
      • Anthem
      • ArcherDX
      • Arm
      • AstraZeneca
      • Atomwise
      • ATUM
      • Avera Health
      • AXA PPP healthcare
      • Ayasdi
      • BASF
      • Bausch & Lomb
      • Bayer
      • BC Platforms
      • Becton Dickinson
      • BenevolentAI
      • Benson Hill Biosystems
      • Berg
      • BERG Analytics
      • Berg Pharma
      • BioBeats
      • Biorelate
      • BlackThorn Therapeutics
      • Body Labs
      • BrainScope
      • Brigham and Women's Hospital
      • Broad Institute
      • Brown University
      • BullFrog AI
      • C4X Discovery
      • Cancer Genetics
      • Cannabics Pharmaceuticals
      • Cardiowise
      • Carnegie Mellon University
      • CAS
      • Ceapro
      • Celgene
      • Centers for Medicare and Medicaid Services
      • Center for Prostate Disease Research
      • Centogene
      • Certis
      • CHDI Foundation
      • Chemi Pharmaceutical
      • Children's Hospital of Philadelphia
      • Christian Doppler Research Association
      • Clinigen
      • Cloudera
      • Cloud Pharmaceuticals
      • Cohen Veterans Bioscience
      • Columbia University
      • Consortium AI
      • Control Flo Medical
      • CrystalGenomics
      • Cyclica
      • Cytobank
      • DASH Analytics
      • Data2Life
      • DecisionQ
      • DEEP 6 AI
      • Department of Defense
      • Department of Veterans Affairs
      • Desktop Genetics
      • Diagnos
      • Diurnal
      • E-Therapeutics
      • Early Signal Foundation
      • EKare
      • EndPoint Technologies
      • EnvoyAI
      • Eroll Grow Tech
      • Evidation Health
      • Fabric Genomics
      • Food and Drug Administration (FDA)
      • Freenome
      • Fujitsu Laboratories of America
      • Garuda Health Services
      • GDM Seeds
      • Genomics
      • Genomics England
      • Georgia Institute of Technology
      • Getinge
      • GE Healthcare
      • GlaxoSmithKline
      • Global Good Fund
      • GNS Healthcare
      • Greenville Health System
      • Guerbet
      • Haga Teaching Hospital
      • Harvard University
      • Health Services Advisory Group
      • Henry M. Jackson Foundation
      • Hill-Rom
      • Horizon Discovery
      • Huawei
      • Human Longevity
      • Ibex Medical Analytics
      • IBM
      • IBM Watson Health
      • Imalogix
      • INC Research
      • Indivumed
      • Ingenza
      • Innovate UK
      • Innovative Medicines Initiative (IMI)
      • Inova Translational Medicine Institute
      • Insilico
      • Intel
      • Intellegens
      • Interprotein
      • Ionis Pharmaceuticals
      • IQVIA
      • Iris Pharma
      • ITUS Corporation
      • Janssen Alzheimer Immunotherapy
      • Janssen Pharmaceuticals
      • Janssen Pharmaceutica NV
      • Janssen Research & Development
      • Johnson & Johnson
      • Johnson & Johnson Innovation
      • Johns Hopkins University
      • John Wiley and Sons
      • Juvenescence
      • J Craig Venter Institute
      • Kaiser Permanente
      • Kantar Health
      • Keen Eye
      • Kyoto University
      • La Jolla Institute for Allergy & Immunology
      • Leidos Holdings
      • Lieber Institute
      • LifeArc
      • Mach7 Technologies
      • Massachusetts General Hospital
      • Massachusetts Institute of Technology
      • Max-Planck
      • Mayo Clinic
      • Medial
      • MEDIAN Technologies
      • Medical University of Graz
      • Medidata Solutions
      • Medopad
      • MedyMatch
      • Melax Technologies
      • Memorial Sloan Kettering Cancer Center
      • Mendel Health
      • Michael J Fox Foundation
      • Microsoft
      • Milner Therapeutics Institute and Consortium
      • Mindstrong Health
      • Molplex Pharmaceuticals
      • Monsanto
      • MORE Health
      • Motic
      • Multiple Myeloma Research Foundation
      • MyHealios
      • Myovant Sciences
      • Nano Global
      • National Healthcare Services (NHS)
      • National Institutes of Health
      • National Institute of Allergy and Infectious Diseases
      • National Institute on Aging
      • National Science Foundation
      • Neiman Institute
      • Nestle
      • NeuroLogica
      • Northeastern University
      • Novartis
      • NTT Medical Center Tokyo
      • Nuance Healthcare
      • NuMedii
      • Numerate
      • Nuritas
      • Nvidia
      • Open Commons Consortium
      • Oxford Genetics
      • Pareto Biotechnologies
      • Parkinson's Institute
      • PathAI
      • Pathway Genomics
      • Pennsylvania Department of Health
      • PeriGen
      • Pfenex
      • Pfizer
      • Pharnext
      • Phenome Networks
      • PhysIQ
      • Ping An Ventures
      • Precision Innovation Network
      • Premier Health Group
      • Qiagen
      • Rady Children's Institute for Genomic Medicine
      • ReadCoor
      • Recursion Pharmaceuticals
      • Regenstrief Institute
      • Reliq Health
      • Reveal Biosciences
      • Revive Therapeutics
      • Revon Systems
      • Rhythm Pharmaceuticals
      • Royal Philips Electronics
      • Rush University Medical Center
      • Salud Interactiva
      • Santen
      • Sanuwave Health
      • Scripps Research Institute
      • Second Genome
      • Selah Genomics
      • Selecta Biosciences
      • Serametrix
      • SmartAction
      • Snap40
      • Socionext
      • SOINN
      • SomaLogic
      • Sonoma Orthopedic Products
      • Sophia Genetics
      • Splice Machine
      • Standigm
      • Stanford University
      • Sun Yat-sen University
      • Takeda Pharmaceutical
      • Tempus
      • Tencent Holdings
      • Teva Pharmaceutical Industries
      • TheraSim
      • The University of Chicago Medicine
      • Thomson Reuters
      • Translational Drug Development
      • Twist Bioscience
      • TwoXAR
      • Ubic
      • Uniformed Services University of the Health Sciences
      • University of California, Davis
      • University of California, San Diego
      • University of California Los Angeles
      • University of Maryland Baltimore
      • University of Miami
      • University of Michigan
      • University of Oxford
      • University of Pittsburgh
      • UPMC
      • US Veterans Administration
      • Utah Genome Project
      • Valeant Pharmaceuticals
      • Varian Medical Systems
      • Verb Surgical
      • Vertex Pharmaceuticals
      • Vir Biotechnology
      • Vitaccess
      • VitalConnect
      • Viviphi
      • Walter Reed Army Institute of Research
      • Ward Medication Management
      • Windber Research Institute
      • WinterLight Labs
      • Wuxi Apptec Laboratory Services
      • WuXi NextCODE Genomics
      • Wyss Institute
      • Xenon Pharmaceuticals
      • XtalPi
      • Yale School of Medicine
    • Artificial Intelligence deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Formulation
    • Artificial Intelligence deals by deal type
      • Asset purchase
      • Co-development
      • Collaborative R&D
      • Co-market
      • CRADA
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Manufacturing
      • Marketing
      • Option
      • Research
      • Spin out
      • Supply
      • Termination
    • Artificial Intelligence deals by therapy area
      • Cardiovascular
      • Long QT syndrome
      • Congestive heart failure
      • Central Nervous System
      • Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease)
      • Parkinson's disease
      • Stroke
      • Traumatic Brain Injury
      • Dental
      • Wound healing
      • Gastrointestinal
      • Genetic disorders
      • Huntington's disease
      • Symptoms
      • Hematology
      • Anemia
      • Hemophilia
      • Hospital care
      • Accident and emergency
      • Surgery
      • Orthopedics
      • Immunology
      • Infectives
      • Bacterial
      • Malaria
      • Metabolic
      • Liver disease
      • Nutrition and vitamins
      • Rheumatoid arthritis
      • Bone fracture
      • Muscular dystrophy
      • Prenatal screening
      • Oncology
      • Bladder cancer
      • Breast cancer
      • Colorectal cancer
      • Leukemia
      • Lung cancer
      • Lymphoma
      • Melanoma
      • Multiple myeloma
      • Pancreatic cancer
      • Prostate cancer
      • Solid tumors
      • Ophthalmics
      • Age-related macular degeneration
      • Cataracts
      • Glaucoma
      • Orphan disease
      • Pediatrics
      • Psychiatry
      • Cognitive impairment
      • Dementia
      • Alzheimers
      • Sleep disorders
      • Sleep apnoea
      • Obesity
      • Asthma
      • Chronic obstructive pulmonary disease
      • Idiopathic pulmonary fibrosis
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report